Cargando…
Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer
Interest in the measurement of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) has increased during the past decade. The analysis of quantitative ctDNA changes as a general response evaluation criterion during systemic treatment is a scientific approach with high clinical potential, and res...
Autores principales: | Spindler, Karen-Lise Garm, Jakobsen, Anders |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154995/ https://www.ncbi.nlm.nih.gov/pubmed/37152423 http://dx.doi.org/10.1177/17588359231171580 |
Ejemplares similares
-
Circulating DNA in patients undergoing loco-regional treatment of
colorectal cancer metastases: a systematic review and
meta-analysis
por: Callesen, Louise B., et al.
Publicado: (2022) -
Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma
por: Topham, James T., et al.
Publicado: (2023) -
Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?
por: Solar Vasconcelos, Joao Paulo, et al.
Publicado: (2022) -
Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer
por: Boutin, Mélina, et al.
Publicado: (2023) -
Association between circulating tumor cells in the peripheral blood and the prognosis of gastric cancer patients: a meta-analysis
por: Jin, Tao, et al.
Publicado: (2023)